H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development

H1 and Novo Nordisk have partnered to enhance clinical trial design and execution using AI-driven workflows and proprietary data, aiming to speed up drug development and improve operational efficiency. H1 will also advance StudyHub, an AI-enabled clinical development platform originally built by Novo Nordisk.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.